Official US documents have disclosed that a popular anti-stroke medicine may have used fictitious data while concealing research on its fatal effects. In 2009, the acclaimed British medical journal, The Lancet, published a prime story on rivaroxaban, a blood thinner medicine, which showed that the treatment was safe and efficient. But recently, the same journal warned of defaults in the trial data and claimed to initiate an investigation over it.

Lancet opens probe into ‘unreliable’ anti-stroke medicine

icahn-school-of-medicine-at-mount-sinai

Icahn School Of Medicine At Mount Sinai, News on Icahn School Of Medicine At Mount Sinai, stories on Icahn School Of Medicine At Mount Sinai, articles on Icahn School Of Medicine At Mount Sinai, Icahn School Of Medicine At Mount Sinai stories at Wion, Icahn School Of Medicine At Mount Sinai news, Icahn School Of Medicine At Mount Sinai latest news

icahn school-of-medicine-at-mount-sinai

Lancet opens probe into ‘unreliable’ anti-stroke medicine